Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered EXACT Sciences from a hold rating to a sell rating in a research report on Thursday, March 28th. UBS Group boosted their target price on EXACT Sciences from $109.00 to $115.00 and gave the stock a buy rating in a research report on Tuesday. Craig Hallum set a $95.00 target price on EXACT Sciences and gave the stock a buy rating in a research report on Friday, February 22nd. Finally, Goldman Sachs Group raised EXACT Sciences from a neutral rating to a buy rating and upped their price target for the company from $85.00 to $120.00 in a research report on Tuesday, February 26th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $100.18.
Shares of EXACT Sciences stock opened at $95.21 on Tuesday. The firm has a market cap of $11.93 billion, a PE ratio of -70.01 and a beta of 1.83. The company has a current ratio of 8.99, a quick ratio of 8.70 and a debt-to-equity ratio of 1.02. EXACT Sciences has a 12-month low of $44.85 and a 12-month high of $99.52.
EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Thursday, February 21st. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.05. The company had revenue of $142.98 million for the quarter, compared to analyst estimates of $143.00 million. EXACT Sciences had a negative return on equity of 23.58% and a negative net margin of 38.54%. EXACT Sciences’s revenue for the quarter was up 63.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.18) earnings per share. Equities research analysts predict that EXACT Sciences will post -1.98 EPS for the current fiscal year.
In related news, insider Mark Stenhouse sold 11,192 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $92.54, for a total transaction of $1,035,707.68. Following the transaction, the insider now directly owns 25,500 shares of the company’s stock, valued at $2,359,770. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jeffrey Thomas Elliott sold 90,909 shares of the company’s stock in a transaction on Thursday, January 24th. The shares were sold at an average price of $78.90, for a total value of $7,172,720.10. Following the transaction, the chief financial officer now directly owns 124,120 shares in the company, valued at $9,793,068. The disclosure for this sale can be found here. Insiders have sold 455,507 shares of company stock worth $37,454,557 over the last three months. 3.20% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. increased its position in EXACT Sciences by 161.0% in the 1st quarter. Meeder Asset Management Inc. now owns 7,594 shares of the medical research company’s stock worth $657,000 after purchasing an additional 4,684 shares during the last quarter. Shine Investment Advisory Services Inc. increased its position in EXACT Sciences by 130.2% in the 1st quarter. Shine Investment Advisory Services Inc. now owns 442 shares of the medical research company’s stock worth $38,000 after purchasing an additional 250 shares during the last quarter. WoodTrust Financial Corp acquired a new position in EXACT Sciences in the 1st quarter worth about $217,000. Gofen & Glossberg LLC IL increased its position in EXACT Sciences by 1.8% in the 1st quarter. Gofen & Glossberg LLC IL now owns 8,375 shares of the medical research company’s stock worth $725,000 after purchasing an additional 150 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB acquired a new position in EXACT Sciences in the 1st quarter worth about $8,662,000. 89.86% of the stock is currently owned by hedge funds and other institutional investors.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Recommended Story: How to interpret a stock’s beta number
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.